folacin 5 mg/1 tableta tableta
farmis d.o.o. sarajevo - folna kiselina - tableta - 5 mg/1 tableta - 1 tableta sadrži: 5 mg folne kiseline
maviret 100 mg/1 tableta+ 40 mg/1 tableta filmom obložena tableta
abbvie d.o.o. - glekaprevir, pibrentasvir - filmom obložena tableta - 100 mg/1 tableta+ 40 mg/1 tableta - 1 filmom obložena tableta sadrži: 100 mg glekaprevira i 40 mg pibrentasvira
noxafil
merck sharp and dohme b.v - posakonazol - candidiasis; mycoses; coccidioidomycosis; aspergillosis - antimikotika za sustavnu uporabu - noxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in adults (see sections 4. 2 i 5. 1):- invasive aspergillosisnoxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections 4. 2 i 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. Огнеупорность definira kao progresiju infekcije ili nedostatak poboljšanja nakon što je minimum 7 dana do terapijske doze učinkovit antifungalna terapija. noxafil gastro-resistant tablets are also indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections 4. 2 i 5. 1):- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis. noxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adults (see sections 4. 2 i 5. 1):- invasive aspergillosisnoxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adult and paediatric patients from 2 years of age (see sections 4. 2 i 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. Огнеупорность definira kao progresiju infekcije ili nedostatak poboljšanja nakon što je minimum 7 dana do terapijske doze učinkovit antifungalna terapija. noxafil concentrate for solution for infusion is also indicated for prophylaxis of invasive fungal infections in the following adult and paediatric patients from 2 years of age (see sections 4. 2 i 5. 1):- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease (gvhd) and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis. noxafil gastro resistant powder and solvent for oral suspension is indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age (see sections 4. 2 i 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. Огнеупорность definira kao progresiju infekcije ili nedostatak poboljšanja nakon što je minimum 7 dana do terapijske doze učinkovit antifungalna terapija. noxafil gastro-resistant powder and solvent for oral suspension is indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2 years of age:- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- haematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis. noxafil oral suspension is indicated for use in the treatment of the following fungal infections in adults (see section 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products;- oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor. Огнеупорность definira kao progresiju infekcije ili nedostatak poboljšanja nakon što je minimum 7 dana do terapijske doze učinkovit antifungalna terapija. noxafil oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients:- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis.
orphacol
theravia - kolesku kiselinu - digestive system diseases; metabolism, inborn errors - Žučnih kiselina i derivata - orphacol je indiciran za liječenje urođene pogreške u primarne žučne kiseline sinteza 3β-hidroksi-Δ5-c27-steroidni oxidoreductase manjak ili nedostatak Δ4-3-oxosteroid-5β-reduktaze u dojenčadi, djece i adolescenata u dobi od jednog mjeseca do 18 godina i odrasle osobe.
kalcijev folinat pliva 10 mg/ml otopina za injekciju/infuziju
pliva hrvatska d.o.o., prilaz baruna filipovića 25, zagreb, hrvatska - kalcijev folinat hidrat - otopina za injekciju/infuziju - 10 mg/ml - urbroj: 1 ml otopine za injekciju sadrži 10 mg folinatne kiseline u obliku kalcijevog folinata
kalcijev folinat pliva 10 mg/ml 100 mg/10 ml otopina za injekciju/ infuziju
pliva d.o.o.sarajevo - kalcijumfolinat - otopina za injekciju/ infuziju - 100 mg/10 ml - 10 ml otopine za injekciju/infuziju sadrži: 100 mg folinska kiselina (u obliku kalcijumfolinata)
kalcijev folinat pliva 10 mg/ml 300 mg/30 ml otopina za injekciju/ infuziju
pliva d.o.o.sarajevo - kalcijumfolinat - otopina za injekciju/ infuziju - 300 mg/30 ml - 30 ml otopine za injekciju/infuziju sadrži: 300 mg folinska kiselina (u obliku kalcijumfolinata)
kalcijev folinat pliva 10 mg/ml 50 mg/5 ml otopina za injekciju/ infuziju
pliva d.o.o.sarajevo - kalcijumfolinat - otopina za injekciju/ infuziju - 50 mg/5 ml - 5 ml otopine za injekciju/infuziju sadrži: 50 mg folinska kiselina (u obliku kalcijumfolinata)
kalcijev folinat pliva 10 mg/ml 500 mg/50 ml otopina za injekciju/ infuziju
pliva d.o.o.sarajevo - kalcijumfolinat - otopina za injekciju/ infuziju - 500 mg/50 ml - 50 ml otopine za injekciju/infuziju sadrži: 500 mg folinska kiselina (u obliku kalcijumfolinata)
latrigil 100 mg/1 tableta tableta za oralnu suspenziju
hemofarm proizvodnja farmaceutskih proizvoda d.o.o. banja luka - lamotrigin - tableta za oralnu suspenziju - 100 mg/1 tableta - 1 tableta za oralnu suspenziju sadrži: 100 mg lamotrigina